Navigation Links
Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Date:5/14/2009

LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.

Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data, 2007 sales of Enlon(R) and Enlon-Plus(R) totaled $2,727,000 and 307,000 units.

Bioniche will supply Enlon(R) in 10 mg/mL, 15 mL vials and Enlon-Plus(R) in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus(R).

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... 2017 , ... When James Sherley, was notified earlier this year that his company Asymmetrex ... 2017 by The Silicon Review , he was not surprised as others might be. ... but this recognition by Silicon Valley was particularly meaningful. Our selection by ...
(Date:5/16/2017)... ... 16, 2017 , ... Cynvenio Biosystems, Inc. a ... Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known ... and accurately identify tumor-related genetic mutations that can be treated with targeted therapies. ...
(Date:5/15/2017)... (PRWEB) , ... May 15, 2017 , ... Tunnell ... in a presentation of “The Key Role of Specifications in Process Validation,” at the ... Philadelphia . The event will bring together leaders from the pharmaceutical and biotech industries ...
(Date:5/15/2017)... , May 15, 2017  IBM (NYSE: IBM ... can stretch double-stranded DNA molecules with the potential ... This technology complements the IBM Research,s ... such as exosomes and which may also contain ... uses an array of diamond shaped micropillars 1 ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):